Products - Blood conditions | Topic

Showing 15 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 December 2025
Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
18 June 2026
Olezarsen for treating familial chylomicronaemia syndrome [ID6585]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
19 August 2026
Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
3 September 2026
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Plozasiran for treating familial chylomicronaemia syndrome [ID6593]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Concizumab for treating haemophilia A or B in people 12 years and over with inhibitors [ID6665]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Blood conditions Products

Filter

Product type

Guidance programme

Status
1 selected

New and updated

Showing 15 products

Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]

Donidalorsen for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6457]

Olezarsen for treating familial chylomicronaemia syndrome [ID6585]

Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]

Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]

Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312

Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]

Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]

Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]

Plozasiran for treating familial chylomicronaemia syndrome [ID6593]

Concizumab for treating haemophilia A or B in people 12 years and over with inhibitors [ID6665]

Blood conditions Products

Filter

Product type

Guidance programme

Status1 selected

New and updated

Showing 15 products

Status
1 selected